Affordable Access

deepdyve-link
Publisher Website

Modified MVAC as a Second-Line Treatment for Patients with Metastatic Urothelial Carcinoma after Failure of Gemcitabine and Cisplatin Treatment.

Authors
  • Lee, Jung Hyun1
  • Kang, Sung Gu2
  • Kim, Seung Tae3
  • Kang, Seok Ho2
  • Choi, In Keun3
  • Park, Young Je4
  • Oh, Sang Chul3
  • Sung, Deuk Jae5
  • Seo, Jae Hong3
  • Cheon, Jun2
  • Shin, Sang Won3
  • Kim, Yeul Hong3
  • Kim, Jun Suk3
  • Park, Kyong Hwa3
  • 1 Korea University College of Medicine, Seoul, Korea. , (North Korea)
  • 2 Department of Urology, Korea University College of Medicine, Seoul, Korea. , (North Korea)
  • 3 Division of Oncology/Hematology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. , (North Korea)
  • 4 Department of Radiation Oncology, Korea University College of Medicine, Seoul, Korea. , (North Korea)
  • 5 Department of Radiology, Korea University College of Medicine, Seoul, Korea. , (North Korea)
Type
Published Article
Journal
Cancer research and treatment : official journal of Korean Cancer Association
Publication Date
Apr 01, 2014
Volume
46
Issue
2
Pages
172–177
Identifiers
DOI: 10.4143/crt.2014.46.2.172
PMID: 24851109
Source
Medline
Keywords
License
Unknown

Abstract

Modified MVAC appears to be a safe and active chemotherapy regimen in patients with stable physical status and adequate renal function after GC treatment.

Report this publication

Statistics

Seen <100 times